TY - JOUR

T1 - Ограничения и возможности лекарственного лечения в условиях пандемии COVID-19

AU - Орлова, Рашида Вахидовна

AU - Каледина, Екатерина Александровна

AU - Малкова, Анна Михайловна

AU - Жукова, Наталья Владимировна

AU - Наймушина, Полина Андреевна

AU - Беляк, Наталья Петровна

AU - Жукова , Анна Егоровна

AU - Демченкова, Александра Сергеевна

AU - Карасева, Нина Алексеевна

AU - Егорова , Инна Валерьевна

AU - Тесленко, К.Н.

AU - Тарасов, Артем Владиславович

N1 - Publisher Copyright: © 2021, Remedium Group Ltd. All rights reserved.

PY - 2021/8/7

Y1 - 2021/8/7

N2 - The COVID-19 pandemic has affected all medical fields and brought up a lot of serious problems. The features of the COVID-19 infection in patients with cancer are important to understand. According to many articles, patients with cancer are more vulnerable to COVID-19 infection. Patients undergoing anticancer treatment have 1-4% morbidity rate. Patients with hematological diseases and lung cancer are at higher risk of SARS-CoV-2 infection and also have more severe symptoms and complications. In this article we discuss the effect of the tumors on the immune system and comprehend the pathogenesis of the coronavirus disease according to its impact on the immunity. Moreover, in the review we analyze available data about the influence of the different types of cancer therapy (chemotherapy, target therapy, radiotherapy and immunotherapy) on the severity of the COVID-19 infection. Evidence on the effect of chemotherapy on severity and mortality from COVID-19 is contradictory. Whereas there are some authors concluding that chemotherapy treatment is not affecting the severity of COVID-19 disease, there are also some works where the connection between these facts was established. At the same time target therapy, radio-and immunotherapy most likely do not worsen the SARS-CoV-2 infection and are not associated with the development of complications. But it’s important to say that the amount of data available for today is insufficient to make a unambiguous conclusion.

AB - The COVID-19 pandemic has affected all medical fields and brought up a lot of serious problems. The features of the COVID-19 infection in patients with cancer are important to understand. According to many articles, patients with cancer are more vulnerable to COVID-19 infection. Patients undergoing anticancer treatment have 1-4% morbidity rate. Patients with hematological diseases and lung cancer are at higher risk of SARS-CoV-2 infection and also have more severe symptoms and complications. In this article we discuss the effect of the tumors on the immune system and comprehend the pathogenesis of the coronavirus disease according to its impact on the immunity. Moreover, in the review we analyze available data about the influence of the different types of cancer therapy (chemotherapy, target therapy, radiotherapy and immunotherapy) on the severity of the COVID-19 infection. Evidence on the effect of chemotherapy on severity and mortality from COVID-19 is contradictory. Whereas there are some authors concluding that chemotherapy treatment is not affecting the severity of COVID-19 disease, there are also some works where the connection between these facts was established. At the same time target therapy, radio-and immunotherapy most likely do not worsen the SARS-CoV-2 infection and are not associated with the development of complications. But it’s important to say that the amount of data available for today is insufficient to make a unambiguous conclusion.

KW - Cancer

KW - Chemotherapy

KW - COVID-19

KW - Immunotherapy

KW - Radiation therapy

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85112368147&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/34fa7d71-65e4-3a18-aa88-10f50a8701c2/

U2 - 10.21518/2079-701X-2021-9-108-113

DO - 10.21518/2079-701X-2021-9-108-113

M3 - статья

AN - SCOPUS:85112368147

VL - 2021

SP - 108

EP - 113

JO - МЕДИЦИНСКИЙ СОВЕТ

JF - МЕДИЦИНСКИЙ СОВЕТ

SN - 2079-7028

IS - 9

ER -